Wisconsin Assembly Bill AB1194

Wisconsin 2023-2024 Regular Session

• Introduced: 4/9/24
• Refer: 4/9/24
• Failed: 4/15/24

Caption

Banning products containing intentionally added PFAS and providing a penalty. (FE)

Impact

This legislation is poised to shift the landscape of product regulation within the state, significantly impacting manufacturers and retailers. By establishing a clear timeline for phasing out PFAS in consumer products, AB1194 disincentivizes the use of these chemicals, which have been linked to various adverse health effects. The bill empowers the Department of Natural Resources (DNR) to enforce the prohibition and requires manufacturers to conduct testing and reporting on their products. This aligns state law with growing public concern over chemical exposure and encourages the transition towards safer alternatives in product development.

Summary

Assembly Bill 1194 aims to protect public health and the environment by banning the sale and distribution of products containing intentionally added perfluoroalkyl and polyfluoroalkyl substances (PFAS). Effective January 1, 2028, the bill prohibits specific categories of products, including food packaging, cleaning products, cosmetics, and textiles that contain these harmful substances. The comprehensive approach includes a complete ban on all such products starting January 1, 2034, thereby reinforcing the state's commitment to eliminating toxic chemicals from consumer goods.

Conclusion

Overall, AB1194 represents a significant legislative effort to mitigate chemical risks and safeguard public health. The comprehensive ban on specific products containing PFAS underscores a proactive approach to environmental health, setting a precedent for future regulatory measures aimed at reducing harmful substances in consumer products. The balance between public health interests and economic considerations remains critical as the bill progresses through the legislative process.

Contention

While the bill has garnered support from environmental advocates and public health officials, it may also face opposition from industry representatives concerned about the economic impact of such regulations. Notably, the bill allows exemptions for products under specific circumstances, such as those governed by federal law or deemed to have unavoidable PFAS use. This aspect may be a point of contention among stakeholders who fear that excessive regulations could hinder product availability and innovation, particularly in industries reliant on chemical formulations.